AMPEL BioSolutions has unveiled a new genetic precision medicine test that can predict heart disease at an early stage in women with lupus.
The new CardioGENE lab test also provides decision support for prophylactic therapies.
It uses blood samples to identify inherited genetic markers that drive pathways with the capacity to be targeted by drugs that can prevent cardiovascular issues.
